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1. Introduction
Glial cells were identified for the first time in the nineteenth century when the French physi-
cian René Dutrochet described for the first time, in 1824, small globules among the large ones 
within the mollusk nervous system. However, we have to wait until 1856 when the German 
pathologist Rudolph Virchow coined the term “nervekitt,” nerve glue, to describe that sort of 
connective tissue of the central nervous system. Subsequently, Santiago Ramon y Cajal, Pio 
del Rio Hortega, and Otto Deiters pioneered this field with their experiments and gave them 
the name “glia” derived from the ancient Greek word that means glue. At that time, glia was 
considered as purely unfunctional glue for neurons [1]. However, research since the mid-
1990 has shown that glia might play a particularly important role in the cognitive function 
as indicated by the correlation between the glia/neuron ratio in brain tissue and the state of 
evolution of species [2]. In fact, C. elegans possesses only 52 glial cells versus 302 neurons with 
a glia-to-neuron ratio of 0.18 [3], whereas the whole human-adult brain has a one-to-one ratio 
[4] and with a ratio of 1.4 in the cerebral cortex [5]. Moreover, comparison of glia-to-neuron 
ratio in different human cortical areas with that of macaques displayed a significant aug-
mentation of the ratio in humans [6]. In the CNS, glia includes astrocytes, oligodendrocytes, 
microglia, and their progenitors NG2 glia and decades of studies demonstrated that they 
have a specific role in brain tissue homeostasis. In particular, astrocytes, whose name derived 
from Greek and means “star-like cell,” are active dynamic signaling players of the central ner-
vous system. They are key regulators of synaptic activity and plasticity, neural network, and 
cognitive functions controlling extracellular ion balance and neurotransmitter homeostasis. 
They perform many functions, including biochemical support of endothelial cells that form 
the blood-brain barrier, provision of nutrients to the nervous tissue, and regulation of neuro-
genesis and brain wiring [7]. Dysfunction of astrocytes can thereby induce major alterations 
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in neuronal functions, contributing to the pathogenesis of several brain disorders. Astrocytes 
participate to a variety of essential physiological processes in the healthy brain such as the 
formation and maturation of the synapses, receptor trafficking, control of the homeostasis of 
ions and energy metabolites, and clearance of neurotransmitters. Astrocytes also regulate the 
extracellular space volume and modulate the synaptic plasticity [8, 9]. Dynamic bidirectional 
signaling between neurons and astrocytes has been extensively demonstrated in experimen-
tal animal models. However, recently Navarrete et al. [10] demonstrated that astrocyte from 
human brain tissue exhibit Ca2+-induced excitability and can respond to neurotransmitters 
released by synapses. Moreover, morphological, genomic, and functional studies revealed 
that human astrocytes display specific characteristics compared to the rodent counterparts. In 
particular, human astrocytes express more proteins involved in calcium signaling and propa-
gate calcium waves at a higher speed compared to murine astrocytes [11]. These observations 
lead to the idea that human astrocytes play an important role in the molding of the higher 
cognitive functions and that they give a significant contribution to cerebral pathology. As a 
matter of fact, transplantation of human astrocytes into mouse brain leads to an improvement 
of higher cognitive functions, such as long-term potentiation (LTP) and learning, pointing 
toward the importance of human astrocytes in the cognitive abilities of human brains [2].
Indeed, even if several neuropathologists, such as Alzheimer, Nissl, and Fromman, speculate 
a glial role in neurodegenerative disorders, until the mid-1990s, the neurocentric paradigm 
dominated. Nevertheless, growing evidences indicate that astroglial dysfunction contributes 
to the pathogenesis of several neurological and psychiatric disorders [12]. A common feature 
of several neurological diseases is reactive astrogliosis.
2. Reactive astrogliosis
Reactive astrogliosis is a spectrum of changes in astrocytes that occur in response of all forms 
of CNS injury and disease. In summary, injured tissues display upregulation of structural pro-
teins, such as glial fibrillary acidic protein (GFAP) and vimentin, and hypertrophy of astrocytes’ 
cell body and processes that elongate around the lesion core and release a cascade of inflamma-
tory signals that can strongly affect the pathological outcome [13]. Moreover, some quiescent 
astrocytes re-enter the cell cycle [14]. However, these hallmarks can vary according to the sever-
ity of the disease and are regulated by inter- and intracellular signaling molecules in a context-
specific manner [15]. In particular, in mild or moderate astrogliosis, which generally occurs 
far from CNS focal lesions, astrocytic proliferation is almost absent and the increased GFAP 
expression together with cell body and process hypertrophy, which is not altering astrocyte 
organization into individual distinct domains, are variable [16]. Moreover, moderate astroglio-
sis also results in the expression of copper-zinc superoxide dismutase, glutathione peroxidase 
or metallothionein, inducible nitric oxide synthase, and release of trophic factors and cytokines, 
including tumor necrosis factor and interleukins and interferons [17]. Furthermore, in mild or 
moderate forms, if the initial triggering insult is removed, reactive astrogliosis can revert and 
cells return to a condition similar to that observed in healthy tissue [15]. On the other hand, near 
focal lesions, severe diffuse astrogliosis is characterized by significantly increased astrocytic 
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proliferation. The molecular factors that induce astrocytes’ proliferation are not completely 
characterized, but several studies ascribe an important role to epidermal growth factor, fibro-
blast growth factor, endothelin 1, ATP, lipopolysaccharide, and nitric oxide [18–21]. Astrocytic 
proliferation causes overlapping of neighboring astrocytic processes with the disruption of the 
individual astrocyte domains and the consequent formation of a compact glial scar. Such scar, 
which represents the hallmark of reactive astrogliosis, is due to astrocyte interaction with differ-
ent cell types of the brain tissue and is characterized by phenomena of necrosis, tumors, chronic 
neurodegeneration, infection, or inflammatory infiltration [15, 21]. These structural changes 
are not reversible and persist also after the resolution of the triggering insult [15]. More impor-
tant, mature glial scars act as barriers to inflammatory cells to protect surrounding healthy 
tissue from nearby areas of intense inflammation. Reactive astrocytes can also protect CNS 
cells and tissue by up-taking excitotoxic glutamate, producing glutathione against oxidative 
stress, degrading amyloid-beta peptides, regulating extracellular space volume and ion bal-
ance, facilitating blood-brain barrier repair, and regulating CNS inflammation. Nevertheless, 
growing evidence also shows that reactive astrocytes can contribute to or be the primary source 
of CNS physiopathology. Reactive astrocytes from glial scars can indeed synthesize collagen 
and sulfate proteoglycans, which prevent axon regeneration [17].
3. Astrocytes: new tools for neurological disease research
Traditionally, astrocytes have been studied as a homogeneous group of cells, even if the 
peculiar morphology of mature mammalian astrocytes was observed since 1865 thanks to 
the studies on mouse brain by Otto Deiters [22]. A detailed morphological study of glial cells 
came from Camillo Golgi and Ramon y Cajal in 1872 who, independently, by means of the 
black staining reaction, observed two different types of astrocytes: the protoplasmic and the 
fibrous astrocytes. However, for a long time, astrocytes received little or no consideration 
as target for neurological studies because the neurocentric paradigm dominated. New and 
recent findings demonstrated that astrocytes are positioned to promote both the regeneration 
of the damaged neurons and to protect existing neurons from degeneration. For this reason, 
astrocytes represent an important focus in the development of new therapeutic tools for neu-
rodegenerative disorder that have been historically viewed as purely neuronal in their pathol-
ogy. Within the past 5 years, important progress has been made deriving astrocytes from 
induced pluripotent stem cells (IPSC). Researchers are now able to generate patients-specific 
astrocytes that recapitulate the patients’ genetic background. Once healthy astrocytes have 
been obtained and characterized, they can be used to replace dying astrocytes or to promote 
the survival of existing neurons. This kind of application has not yet been tested in humans; 
however, there is a growing body of in vitro and in vivo evidence that indicates that these 
therapies would be beneficial for many neuronal diseases [23]. Indeed, in an amyotrophic 
lateral sclerosis (ALS) mouse model, researchers have shown that the direct transplantation 
of human (h)iPSC-derived neural progenitor cells prolonged the lifespan of the animal [24]. In 
these experiments, NPCs differentiated into astrocytes and exhibited an upregulation of vas-
cular endothelial growth factor (VEGF), which induces the activation of the AKT-dependent 
intracellular signaling, which has previously been shown to be important for cell survival 
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and proliferation in ALS [25]. The authors also hypothesized that the introduction of progen-
itor-derived astrocytes with normal expression of glucose transporters could restore glucose 
homeostasis in this model [26]. Moreover, these versatile human astrocytes could be used 
alone or in co-culture with neurons in both target-based and phenotypic high-throughput 
drug-screening research studies, promoting the discovery of novel therapeutics tools useful 
in the treatment of neurodegenerative disorders. For decades, therapeutic development for 
neurodegenerative disorders has focused only on diseased neurons. Due to the crucial role of 
astrocytes in physiology of the central nervous system and in the pathogenesis of several neu-
rodegenerative diseases, it is not surprising that the traditional drug development strategy 
which follows the neurocentric paradigm has not produced effective therapies. Developing 
new drugs that complement and combine therapies which target both neuronal and astrocytic 
degeneration could provide a new direction to increase the success of therapeutic develop-
ment for neurodegenerative diseases in the future. The shift from a neurocentric view to one 
that incorporates astrocytes in disease models for drug discovery is a critical step in renewing 
drug development strategies to treat neurodegenerative diseases.
Author details
Maria Teresa Gentile* and Luca Colucci D’Amato
*Address all correspondence to: matergen@yahoo.it
Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, 
University of Campania “Luigi Vanvitelli”, Caserta, Italy
References
[1] Kettenmann H, Ransom BR. The Concept of Neuroglia: A Historical Perspective. In 
Neuroglia. Oxford University Press; 2013. DOI: http://dx.doi.org/10.1093/acprof:oso/ 
9780195152227.003.0001
[2] Han X, Chen M, Wang F, Windrem M, Wang S, Shanz S, Xu Q, Oberheim NA, Bekar L, 
Betstadt S, Silva AJ, Takano T, Goldman SA, Nedergaard M. Forebrain engraftment by 
human glial progenitor cells enhances synaptic plasticity and learning in adult mice. 
Cell Stem Cell. 2013;12(3):342-353
[3] Oikonomou G, Shaham S. The glia of Caenorhabditis elegans. Glia. 2011;59(9):1253-1263
[4] Azevedo FA, Carvalho LR, Grinberg LT, Farfel JM, Ferretti RE, Leite RE, Jacob Filho W, 
Lent R, Herculano-Houzel S. Equal numbers of neuronal and nonneuronal cells make 
the human brain an isometrically scaled-up primate brain. The Journal of Comparative 
Neurology. 2009;513(5):532-541
[5] Pelvig DP, Pakkenberg H, Stark AK, Pakkenberg B. Neocortical glial cell numbers in 
human brains. Neurobiology of Aging. 2008;29(11):1754-1762
Astrocyte - Physiology and Pathology6
[6] Sherwood CC, Stimpson CD, Raghanti MA, Wildman DE, Uddin M, Grossman LI, 
Goodman M, Redmond JC, Bonar CJ, Erwin JM, Hof PR. Evolution of increased glia-
neuron ratios in the human frontal cortex. Proceedings of the National Academy of 
Sciences of the United States of America. 2006;103(37):13606-13611
[7] Vasile F, Dossi E, Rouach N. Human astrocytes: Structure and functions in the healthy 
brain. Brain Structure & Function. 2017;222(5):2017-2029
[8] Araque A, Carmignoto G, Haydon PG, Oliet SH, Robitaille R, Volterra A. Gliotransmitters 
travel in time and space. Neuron. 2014;81(4):728-739
[9] Dallérac G, Rouach N. Astrocytes as new targets to improve cognitive functions. Progress 
in Neurobiology. 2016;144:48-67
[10] Navarrete M, Perea G, Maglio L, Pastor J, García de Sola R, Araque A. Astrocyte calcium 
signal and gliotransmission in human brain tissue. Cerebral Cortex. 2013;23(5):1240-1246
[11] Bazargani N, Attwell D. Astrocyte calcium signaling: The third wave. Nature Neuroscience. 
2016;19(2):182-189
[12] Dossi E, Vasile F, Rouach N. Human astrocytes in the diseased brain. Brain Research 
Bulletin. 2018;136:139-156
[13] Sofroniew MV. Astrocyte barriers to neurotoxic inflammation. Nature Reviews. 
Neuroscience. 2015;16(5):249-263
[14] Buffo A, Vosko MR, Ertürk D, Hamann GF, Jucker M, Rowitch D, Götz M. Expression 
pattern of the transcription factor Olig2 in response to brain injuries: Implications for 
neuronal repair. Proceedings of the National Academy of Sciences of the United States 
of America. 2005;102(50):18183-18188
[15] Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. 
Trends in Neurosciences. 2009;32(12):638-647
[16] Wilhelmsson U, Bushong EA, Price DL, Smarr BL, Phung V, Terada M, Ellisman MH, 
Pekny M. Redefining the concept of reactive astrocytes as cells that remain within their 
unique domains upon reaction to injury. Proceedings of the National Academy of 
Sciences of the United States of America. 2006;103(46):17513-17518
[17] Chen Y, Swanson RA. The glutamate transporters EAAT2 and EAAT3 mediate cysteine 
uptake in cortical neuron cultures. Journal of Neurochemistry. 2003;84(6):1332-1339
[18] Gadea A, Schinelli S, Gallo V. Endothelin-1 regulates astrocyte proliferation and reac-
tive gliosis via a JNK/c-Jun signaling pathway. The Journal of Neuroscience. 2008;28(10): 
2394-2408
[19] Levison SW, Jiang FJ, Stoltzfus OK, Ducceschi MH. IL-6-type cytokines enhance epider-
mal growth factor-stimulated astrocyte proliferation. Glia. 2000;32(3):328-337
[20] Neary JT, Zimmermann H. Trophic functions of nucleotides in the central nervous sys-
tem. Trends in Neurosciences. 2009;32(4):189-198
Introductory Chapter: The Importance of Astrocytes in the Research of CNS Diseases
http://dx.doi.org/10.5772/intechopen.74710
7
[21] Sofroniew MV, Vinters HV. Astrocytes: Biology and pathology. Acta Neuropathologica. 
2010;119(1):7-35
[22] Deiters VS, Guillery RW. Otto Friedrich Karl Deiters (1834-1863). The Journal of 
Comparative Neurology. 2013;521(9):1929-1953
[23] Gorshkov K, Aguisanda F, Thorne N, Zheng W. Astrocytes as targets for drug discovery. 
Drug Discovery Today. 2018. pii: S1359-6446(17)30472-5
[24] Kondo T, Funayama M, Tsukita K, Hotta A, Yasuda A, Nori S, Kaneko S, Nakamura M, 
Takahashi R, Okano H, Yamanaka S, Inoue H. Focal transplantation of human iPSC-
derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Reports. 
2014;3(2):242-249
[25] Lunn JS, Sakowski SA, Kim B, Rosenberg AA, Feldman EL. Vascular endothelial growth 
factor prevents G93A-SOD1-induced motor neuron degeneration. Developmental 
Neurobiology. 2009;69(13):871-884
[26] Hall CE, Yao Z, Choi M, Tyzack GE, Serio A, Luisier R, Harley J, Preza E, Arber C, Crisp 
SJ, Watson PMD, Kullmann DM, Abramov AY, Wray S, Burley R, Loh SHY, Martins LM, 
Stevens MM, Luscombe NM, Sibley CR, Lakatos A, Ule J, Gandhi S, Patani R. Progressive 
motor neuron pathology and the role of astrocytes in a human stem cell model of VCP-
related ALS. Cell Reports. 2017;19(9):1739-1749
Astrocyte - Physiology and Pathology8
